Design principles of the cytotoxic CD8 + T cell response
Proceedings of the National Academy of Sciences · 28.04.2026 · 123 (17)
DOI: 10.1073/pnas.2528202123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 24.04.2026. Verfasst von Obinna A Ukogu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Mathematics, University of Washington, Seattle, WA 98105. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Models, Immunological. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, HHS | NIH | National Cancer Institute (NCI), National Science Foundation (NSF).
Abstract (Originalsprache)
Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T cell responses emerge from cellular decision-making remain elusive. Here, we recast the T cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation, and death are regulated through antigenic, pro- and anti-inflammatory cues. By exploring a broad class of feedback-controller designs as potential immune programs, we demonstrate how the speed and magnitude of T cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T cell responses by hierarchical sensitivity to different immune signals. Notably, we find the designs that balance harm from acute infections and autoimmunity produce immune responses consistent with the experimentally observed patterns of T cell effector expansion in mice. Extending our model to immune-based T cell therapies for cancer tumors, we quantify the trade-off between the affinity for tumor antigens (“quality”) and the abundance (“quantity”) of infused T cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T cells. Our findings offer a unified control-logic for cytotoxic T cell responses and point to specific regulatory programs that can be engineered for more robust T cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Applied Mathematics, University of Washington, Seattle, WA 98105.
- Department of Physics, University of Washington, Seattle, WA 98195.
- Immunodynamics Group, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.
- Allen School of Computer Science and Engineering, University of Washington, Seattle, WA 98195.
- Herbold Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA 98109.
- Yale Center for Systems and Engineering Immunology, Yale University, New Haven, CT 06510.
ORCID-Profile: Obinna A Ukogu, Grégoire Altan-Bonnet, Armita Nourmohammad
Förderung
- NIGMS NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- National Science Foundation (NSF)
- HHS | National Institutes of Health
Zitieren
APA
Ukogu, O. A., Montague, Z., Altan-Bonnet, G., & Nourmohammad, A. (2026). Design principles of the cytotoxic CD8 + T cell response. Proceedings of the National Academy of Sciences, 123(17). https://doi.org/10.1073/pnas.2528202123
Vancouver
Ukogu OA, Montague Z, Altan-Bonnet G, Nourmohammad A. Design principles of the cytotoxic CD8 + T cell response. Proceedings of the National Academy of Sciences. 2026;123(17). doi:10.1073/pnas.2528202123
BibTeX
@article{Ukogu2026,
author = {Ukogu, Obinna A and Montague, Zachary and Altan-Bonnet, Grégoire and Nourmohammad, Armita},
title = {Design principles of the cytotoxic CD8 + T cell response},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {17},
doi = {10.1073/pnas.2528202123}
}
EUVIMED